Analyser av Cyxone

Cyxone: Utfall i företrädesemission - Penser

Utfall i företrädesemission Bolaget annonserade under gårdagen utfallet i företrädesemissionen som pågick 7–21 november 2023.

Redeye comments on Cyxone’s Q1 report and potential impact on the new strategy.

Redeye comments on Cyxone’s recently announced strategy that focuses on lead project Rabeximod in RA.

We give a short comment on the additional information from the phase II trial with Rabeximod in Covid-19 patients.

Redeye comments on Cyxone’s Q4 report and summarize our view of progress in 2021.

Cyxone står inför flera händelser som kan leda till en större uppvärdering.

Redeye comments on Cyxone’s Q2 report, that offered no surprises.